Sulforaphane Skin Health Randomized Trial: What the Evidence Says

Quick Answer

Sulforaphane Skin Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Almost all of the more than 80 studies addressing SF synergies provide evidence in cell lines or animal models, with many of them utilizing the gold-standard Chou-Talalay method to quantify synergy, rather than merely asserting it without quantitative support. [Fahey Jed W. (2026); evidence level 3]
• As a result, it is difficult to determine which findings are broadly reproducible, which are model-specific, and which combinations have the strongest translational rationale. [Fahey Jed W. (2026); evidence level 3]
• Acne, as one of the most common skin conditions, is prevalent among 85-90% of adolescents and young adults, and sunburn is almost universally experienced, with acute and long-term consequences including an increased risk of cutaneous malignancy. [Liu Hua (2026); evidence level 3]
• In acne, current evidence supports a more complex pathogenesis involving sebaceous gland biology, follicular hyperkeratinization, host-microbiome interactions, and dysbiosis, rather than simple bacterial overgrowth alone. [Liu Hua (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For sulforaphane skin health randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Fahey Jed W. (2026). Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan †. DOI: 10.3390/medicines13020016. PMCID: PMC13214911. PMID: 42201192. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13214911/
• Liu Hua (2026). Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives. DOI: 10.3390/nu18091444. PMCID: PMC13165143. PMID: 42124049. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13165143/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.